Type B chronic lymphocytic leukemia (CLL-B) is the most common type of leukemia in adults and the elderly. It is characterized by different clinical expressions depending on the patient’s age or gender. Among the factors that control and regulate the apoptosis process, progression of the disease in the patients, p-53 protein and p-21 protein are considered to be of major importance. Over the last decade, several paraclinical investigation methods have been identified to predict the progression of the disease. It was discovered in the last few years that the production of some percentage of mutant p-53 proteins, with the increased stability in type B lymphocytes, leads to the carcinogenesis process. This discovery led to the identification and quantification of the p-53 protein by different methods such as immunohistochemistry (IHC), polymerase chain reaction (PCR), singlestranded peptide microarray, (SSPMa), next-generation sequencing (NGS), and the sandwich enzyme-linked immune sorbent assay (sandwich ELISA).